<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

SmartTRAK Life Sciences News and Analysis Blog

Doug Devens

20 years of diverse medical device experience, including leading companies 3M, Coloplast and Boston Scientific, along with emerging companies. Leadership experience in product development, including championing the process for voice of customer and concept feedback sessions with key thought leaders.

Recent Posts

2 min read

A Tale of Two Recoveries: US Hemostats & Sealants Q121 Market Recap

By Doug Devens on 6/3/21 9:30 AM

The US market for Hemostats and Sealants resumed its growth in Q121 as procedures climbed back towards normal.

While surgical procedures have not fully regained their pre-COVID levels, the US Hemostats and Sealants market grew in Q121 according to SmartTRAK Financial Dashboard. However, it continued to be a tale of two recoveries. CryoLife* and especially JNJ/Ethicon* posted solid gains for the quarter. However, as elective procedures continue to be behind pre-COVID levels, other manufacturers lagged by comparison.

Among the many topics covered in detail in our comprehensive   Q121 Hemostats and Sealants Market Recap *  are:
Topics: Wound Care
Continue Reading
2 min read

Breast & Hernia Procedures Stall: Q420/FY20 US Surgical Matrices Market Recap

By Doug Devens on 3/11/21 9:20 AM

The recovery in breast and hernia procedure stalled in Q420, with revenue dropping -9.2% YoY, according to BioMedGPS’ SmartTRAK Financial DashboardAbbVie* maintained its lead despite the effects of the pandemic, off -8.4% YoY, as its breast matrices continued to lag in the overall recovery. Becton Dickinson* (BD) slid –1.2% YoY as hernia procedures bounced back to normal levels a little faster ...

Among the many topics covered in the comprehensive Q420/FY20 US Surgical Matrices Market Recap* are:
Topics: Wound Care
Continue Reading
2 min read

US Hemostats and Sealants Climb Back: Q420/FY20 Market Recap

By Doug Devens on 3/3/21 8:00 AM

The US market for Hemostats and Sealants continued back toward its pre-pandemic levels, gaining +20.0% QoQ and up +1.1% YoY. For FY20, the market declined, as COVID-19 delayed procedures in Q220 proved too much to overcome.

As the US Healthcare system learned to navigate the new normal and elective procedures continued their return toward COVID-19 levels, the US Hemostats and Sealants market finally exceeded pre-pandemic levels, up +1.1% YoY according to SmartTRAK Financial Dashboard. However, for the year the market was down as Q220’s delayed procedures proved too much to overcome.

Among the many topics covered in the comprehensive Q420/FY20 US Hemostats and Sealants Market Recap* are:

Continue Reading
2 min read

A Journey Back to Normalcy: Q320 Hemostats and Sealants Market Recap

By Doug Devens on 12/7/20 9:58 AM

The US market for Hemostats and Sealants began the journey back to normalcy, slipping -0.2% YoY in Q320, as elective surgeries began to be performed again. Hemostats led the charge with Sealants not far behind.

As the US healthcare system begins to manage COVID-19 and elective procedures return toward pre-COVID-19 levels, the US Hemostats and Sealants market rebounded with a drop of only -0.2% YoY in Q320 according to SmartTRAK Financial Dashboard. Most manufacturers still experienced declines in Q320, but far narrower than the losses of Q220. Ethicon* managed a +4.5% gain in Q320 while the other manufacturers essentially treaded water with respect to Q319.

Among the many topics covered in the comprehensive Q320 US Hemostats and Sealants Market Recap* are:

Topics: Wound Care
Continue Reading
2 min read

Rebounding to Pre-COVID Levels: Q320 US Surgical Matrices Market Recap

By Doug Devens on 12/3/20 3:26 PM

The US Surgical Matrices Market rebounded toward pre-COVID-19 levels in Q320 as the numbers of hernia and breast surgeries came closer to normal levels. The recovery was somewhat uneven, with Breast Matrices still off -8.6% YoY, while Hernia Matrices were closer to pre-COVID-19 levels, off -2.5% YoY.

As hospitals began to establish a new normal in the time of COVID-19, the US Surgical Matrices Market rebounded to lose only -4.6% YoY according to BioMedGPS’ SmartTRAK Financial Dashboard. AbbVie* (formerly Allergan) held on to its lead despite the effects of the pandemic, as its breast-heavy portfolio showed a slower return to normal. Becton Dickinson* (BD) lost less than AbbVie/Allergan, declining –3.5% YoY, as hernia procedures bounced back to normal levels a little faster.

Among the many topics covered in the comprehensive Q320 US Surgical Matrices Market Recap* are:

Topics: Wound Care
Continue Reading
1 min read

Increased COVID Headwinds Shut Down Procedures: Q220 Trauma Market Recap

By Doug Devens on 9/17/20 10:45 AM

Headwinds increased in Q2 as COVID-19 shut down elective procedures and stay-at-home orders impacted trauma volumes, but by the end of the quarter tailwinds picked up and it was smooth flying.

Q220 started out in a stall and continued to nosedive, as the Trauma segment experienced decreased admissions in April and May due to stay at home orders that caused a decrease in daily activities, including limited driving for most of the US. The US Trauma Market was down -14.2% YoY, with WW revenues declining -16.2%.

In June tailwinds picked up as stay at home orders began to lift and activities resumed, which boded well for the Trauma segment. Trauma procedures started to rebound in June, as most hospitals resumed surgeries depending upon PPE and OR time and resources. 

Among the many topics covered in the comprehensive Q220 Trauma Market Recap* are:

Continue Reading
2 min read

The Market Collapses: Q220 US Surgical Matrices Recap

By Doug Devens on 9/14/20 9:17 AM

The US Surgical Matrices Market collapsed in Q220, achieving sales of $227.3MM, off -39.4% YoY, as the effects of COVID-19 became evident with many delayed or canceled surgeries. The problems were evident everywhere, where Breast Matrices dropped -46.4 YoY to $69.6MM in Q220, while Hernia Matrices fell off -35.7% YoY to $157.7MM.

With COVID’s toll on delayed and canceled elective surgeries affecting all participants in the market, the US Surgical Matrices Market yielded -39.4% YoY, according to BioMedGPS’ SmartTRAK Financial DashboardAllergan* held on to its lead despite the effects of the pandemic, giving back -46.9%. Becton Dickinson* (BD) lost less than Allergan, declining -36.8%. However, Medtronic* announced that its hernia business was recovering faster than it expected.

Among the many topics covered in the comprehensive Q220 US Surgical Matrices Market Recap* are:

Continue Reading
2 min read

A Precipitous Drop: Q220 US Hemostats and Sealants Market Recap

By Doug Devens on 9/10/20 9:33 AM

The US market for Hemostats and Sealants dropped precipitously by -32.4% YoY in Q220, as the effects of COVD-19 became evident with many delayed or canceled surgeries.

With COVID’s toll on delayed and canceled elective surgeries affecting all participants in the market, the US Hemostats and Sealants market dropped -32.4% in Q220 according to SmartTRAK Financial Dashboard, a decrease that was presaged in Q120 earnings reports. Baxter* led the decline in Q220, down -42.1% YoY, with the Company’s sealants experiencing the worst YoY shrinkage. Cryolife* was close behind as its BioGlue* franchise saw cardiac surgeries postponed nationwide. In Q220, Ethicon* remained the market leader, followed by Baxter.

Among the many topics covered in the comprehensive Q220 US Hemostats and Sealants Market Recap* are:

Continue Reading
5 min read

Treading Water: Q120 US Surgical Matrices Market Recap

By Doug Devens on 7/9/20 10:21 AM

The US Surgical Matrices Market treaded water in Q120, up +1.6%, as the impact of COVID-19 began to be felt broadly at the end of a quarter that had initially started with good growth.

In Q120, the US Surgical Matrices Market grew +1.6% YoY according to BioMedGPS’ SmartTRAK Financial Dashboard. Allergan* maintained its lead despite the slowdown in breast augmentation and reconstruction surgeries due to COVID-19, gaining +3.4% YoY. Becton Dickinson* (BD) also had been growing well until COVID-19 slowed hernia surgeries, and, like many other companies, warned that Q220 would be far worse since the impact of COVID-19 would be felt at the beginning of the quarter.

Among the many topics covered in the comprehensive Q120 US Surgical Matrices Market Recap* are:

Topics: Wound Care
Continue Reading
6 min read

Hemostats and Sealants Up Despite COVID-19: Q120 Market Report

By Doug Devens on 7/1/20 10:24 AM

The US market for Hemostats and Sealants grew +6.1% YoY in Q120, up from the pace of Q419 despite the late appearance of COVD-19 in the last few weeks of the quarter. Growth was slightly higher in the Hemostats market, with +6.8% growth driven by relative strength in thrombin hemostats.

As reported in SmartTRAK Financial Dashboard, the US Hemostats and Sealants market had a growth rate of +6.1% in Q120. Leading the way in Q120 was Baxter* with +11.6% YoY growth and continued strength from Tisseel* and Artiss* fibrin sealants. Becton Dickinson* (BD) also posted strong gains as its relaunched Progel* and continued its resurgence in Q120. However, all manufacturers predicted that second-quarter results would be much worse since the full effect of surgery deferrals would be felt for the entire quarter. Some manufacturers warned that revenues were reduced as much as...

Among the many topics covered in the comprehensive Q120 Hemostats and Sealants Market Recap* are:

Topics: Wound Care
Continue Reading

    Recent Articles